Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin + myo-inositol
- Development stage
- Unknown
- Lead developer
- Rashid Latif Medical College
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Metformin + myo-inositol is a combination therapy being investigated for the management of polycystic ovary syndrome (PCOS). Metformin is a biguanide small molecule that acts as an insulin sensitizer by activating AMP-activated protein kinase (AMPK), which leads to reduced hepatic glucose production and improved peripheral insulin sensitivity. Myo-inositol is a carbocyclic sugar that serves as a second messenger in the insulin signaling pathway and is involved in follicle-stimulating hormone (FSH) signaling, potentially improving oocyte quality and ovulation. This specific combination is being evaluated in a randomized, double-blind clinical trial conducted by Rashid Latif Medical College (NCT04204044) to compare its efficacy against monotherapy in restoring spontaneous menstrual cycles, reducing body mass index (BMI), and improving the overall biochemical and clinical profile of women with PCOS.
- Other names
- Metformin Hydrochloride + Myo-inositolMetformin/Myo-inositol combination
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)SLC2A4 (Solute carrier family 2 facilitated glucose transporter member 4)
Beyond the preview
Go deeper on metformin + myo-inositol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin + myo-inositol.